SavedAdd your journal

Journals / Turkish Journal of Biology / 2017 / Cilt: 41 - Sayı: 3

Aftermath of the Human Genome Project: an era of struggle and discovery

Zainab HAMDOUN
Hashimul EHSAN
Pages
403–418
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Consider it an invitation to reflect on the fruits of the genomic era.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The collaboration between the Human Genome Project and the Sanger Institute, spurred on by their contemporary- Celera Genomics, in the race to sequence the human genome, opened the door to a generation of research concerned with the study of the nucleic manual.
📊
Key Findings & Data:Following this monumental achievement, the genomic era was born, heralding the development of gene therapy, personalized medicine, pharmacogenomics, and CRISPR/Cas9 gene-editing systems.
💡
Conclusion & Impact:Consider it an invitation to reflect on the fruits of the genomic era.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The collaboration between the Human Genome Project and the Sanger Institute, spurred on by their contemporary- Celera Genomics, in the race to sequence the human genome, opened the door to a generation of research concerned with the study of the nucleic manual. Following this monumental achievement, the genomic era was born, heralding the development of gene therapy, personalized medicine, pharmacogenomics, and CRISPR/Cas9 gene-editing systems. These omic disciplines offer a wide range of applications in the treatment of disease and the betterment of the quality of human life. Their notability, however, manifests in the unique mix of sociological and scientific discourse that ensues. Current genomic-era milestones present a unique opportunity to view scientific advance in a thoughtful light, lacing together discoveries, history, and ethical questions, while encouraging the public to consider the varied facets of this scientific evolution with the same curiosity and enthusiasm as the trailblazers of the Human Genome Project. Consider it an invitation to reflect on the fruits of the genomic era.

🔖

Cite This Article

HAMDOUN, Z., EHSAN, H. (2022). Aftermath of the Human Genome Project: an era of struggle and discovery. Turkish Journal of Biology, Cilt: 41 - Sayı: 3, 403–418. https://ajindex.com/articles/600317

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ai J, Wang D, Wei Q, Li H, Gao G (2016). Adeno-associated virus serotype vectors efficiently transduce normal prostate tissue and prostate cancer cells. Eur Urol 69: 179-181.
  2. Anderson WF (2000). Gene therapy. The best of times, the worst of times. Science 288: 627-629.
  3. Austin CP (2004). The impact of the completed human genome sequence on the development of novel therapeutics for human disease. Annu Rev Med 55: 1-13.
  4. Bainbridge JWB, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, Georgiadis A, Mowat FM, Beattie SG, Gardner PJ et al. (2015). Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med 372: 1887-1897.
  5. Baird RD, Caldas C (2013). Genetic heterogeneity in breast cancer: the road to personalized medicine? BMC Med 11: 151. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, Corn JE, Daley GQ, Doudna JA, Fenner M et al. (2015). A prudent path forward for genomic engineering and germline gene modification. Science 348: 36-38.
  6. Barrangou R (2014). Cas9 targeting and the CRISPR revolution. Science 344: 707-708.
  7. Berg P (2006). Origins of the human genome project: why sequence the human genome when 96% of it is junk? Am J Hum Genet 79: 603-605.
  8. Bissonnette L, Bergeron MG (2012). Infectious disease management through point-of-care personalized medicine molecular diagnostic technologies. J Pers Med 2: 50-70.
  9. Browman G, Hébert PC, Coutts J, Stanbrook MB (2011). Personalized medicine: a windfall for science, but what about patients? Can Med Assoc J 183. Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV, van der Oost J (2008). Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321: 960-964.
  10. Cavazanna-Calvo M, Fischer A (2007). Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest 117: 1456-1465.
  11. Celniker SE, Dillon LA, Gerstein MB, Gunsalus KC, Henikoff S, Karpen GH, Kellis M, Lai EC, Lieb JD, MacAlpine DM et al. (2009). Unlocking the secrets of the genome. Nature 459: 927- 930. Chan IS, Ginsburg GS (2011). Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 12: 217-244.
  12. Chin L, Andersen JN, Futreal PA (2011). Cancer genomics: from discovery science to personalized medicine. Nature Med 17: 297-303.
  13. Collins FS, McKusick VA (2001). Implications of the human genome project for medical science. JAMA 285: 540-544.
  14. Collins FS, Morgan M, Patrinos A (2003). The human genome project: lessons from large-scale bio